FDA Discloses Safety Reviews Of Arcoxia, Prexige and Parecoxib

Merck's Arcoxia (etoricoxib) shows an increase in cardiovascular adverse events in "a number of analyses," FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review